These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 20826614)

  • 1. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.
    Radosevic K; Rodriguez A; Lemckert AA; van der Meer M; Gillissen G; Warnar C; von Eyben R; Pau MG; Goudsmit J
    Clin Vaccine Immunol; 2010 Nov; 17(11):1687-94. PubMed ID: 20826614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guérin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice.
    Arama C; Assefaw-Redda Y; Rodriguez A; Fernández C; Corradin G; Kaufmann SH; Reece ST; Troye-Blomberg M
    Vaccine; 2012 Jun; 30(27):4040-5. PubMed ID: 22521849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
    Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
    Biswas S; Spencer AJ; Forbes EK; Gilbert SC; Holder AA; Hill AV; Draper SJ
    J Immunol; 2012 May; 188(10):5041-53. PubMed ID: 22504652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans.
    Kazmin D; Nakaya HI; Lee EK; Johnson MJ; van der Most R; van den Berg RA; Ballou WR; Jongert E; Wille-Reece U; Ockenhouse C; Aderem A; Zak DE; Sadoff J; Hendriks J; Wrammert J; Ahmed R; Pulendran B
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2425-2430. PubMed ID: 28193898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
    McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
    Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
    Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
    J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver-Directed AAV8 Booster Vaccine Expressing
    Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
    Front Immunol; 2021; 12():612910. PubMed ID: 34248928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein.
    Wang R; Epstein J; Charoenvit Y; Baraceros FM; Rahardjo N; Gay T; Banania JG; Chattopadhyay R; de la Vega P; Richie TL; Tornieporth N; Doolan DL; Kester KE; Heppner DG; Norman J; Carucci DJ; Cohen JD; Hoffman SL
    J Immunol; 2004 May; 172(9):5561-9. PubMed ID: 15100299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
    Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
    Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge.
    Hutchings CL; Birkett AJ; Moore AC; Hill AV
    Infect Immun; 2007 Dec; 75(12):5819-26. PubMed ID: 17908809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
    Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
    Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.
    Shott JP; McGrath SM; Pau MG; Custers JH; Ophorst O; Demoitié MA; Dubois MC; Komisar J; Cobb M; Kester KE; Dubois P; Cohen J; Goudsmit J; Heppner DG; Stewart VA
    Vaccine; 2008 Jun; 26(23):2818-23. PubMed ID: 18455276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime-boost vectored malaria vaccines: progress and prospects.
    Hill AV; Reyes-Sandoval A; O'Hara G; Ewer K; Lawrie A; Goodman A; Nicosia A; Folgori A; Colloca S; Cortese R; Gilbert SC; Draper SJ
    Hum Vaccin; 2010 Jan; 6(1):78-83. PubMed ID: 20061802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
    Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
    Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
    Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
    PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.
    Sun P; Schwenk R; White K; Stoute JA; Cohen J; Ballou WR; Voss G; Kester KE; Heppner DG; Krzych U
    J Immunol; 2003 Dec; 171(12):6961-7. PubMed ID: 14662904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.
    Rodríguez A; Goudsmit J; Companjen A; Mintardjo R; Gillissen G; Tax D; Sijtsma J; Weverling GJ; Holterman L; Lanar DE; Havenga MJ; Radosevic K
    Infect Immun; 2008 Apr; 76(4):1709-18. PubMed ID: 18212075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.